Quick Facts
| Property | Value |
|---|---|
| Category | Erythropoietin-Derived Tissue Protective Peptide |
| Risk Level | Moderate |
| Administration | Subcutaneous or Intramuscular Injection |
| Typical Frequency | Once or Twice Daily |
| Estimated Half-Life | Approximately 2–5 Minutes |
| Primary Research Interest | Nerve Repair / Inflammation Reduction / Tissue Protection |
This material is provided strictly for educational and informational purposes related to peptide research and tissue-protective compounds. ARA-290 is a biologically active experimental peptide that may influence inflammatory and neurological signaling pathways. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
1. Reconstitution Guide
- Vial Size: 10 mg
- Dilutant Type: BAC Water
- Amount of Dilutant Added: 2 mL
- Final Concentration: 5.00 mg/mL
At this concentration:
• 2 mg = 0.400 mL (40.0 units)
• 4 mg = 0.800 mL (80.0 units)
2. Route of Administration
ARA-290 is most commonly administered as a subcutaneous injectable peptide, though intramuscular administration is also discussed in some research and anecdotal contexts.
- Primary Route: SubQ Injection
- Alternative Route: Intramuscular Injection
- Administration Notes: Due to the extremely short half-life, consistent administration timing is considered important for maximal effect
3. Typical Research Protocols
- Product Strength: 5.00 mg/mL
- Typical Delivered Amount: 2–4 mg daily, not to exceed 8 mg per day
- Frequency: Once or twice daily due to the short half-life
- Cycle Length: 8 weeks on / 4 weeks off
- Special Notes: Longer runs are sometimes discussed but may demonstrate diminishing returns. The very short half-life of this peptide means that consistent timing and administration are considered important for maximal effect.
4. Summary
ARA-290 is an experimental peptide derived from erythropoietin (EPO) signaling pathways, specifically engineered to target tissue-protective and anti-inflammatory mechanisms without substantially stimulating red blood cell production.
Research interest in ARA-290 primarily centers around neuropathy, nerve repair, inflammation modulation, chronic pain support, and tissue protection.
5. Mechanism of Action
ARA-290 selectively activates innate repair receptor (IRR) pathways associated with tissue protection and inflammatory modulation.
Unlike full erythropoietin signaling, ARA-290 was designed to minimize erythropoietic activity while preserving regenerative and anti-inflammatory properties.
Potential downstream effects discussed in research include:
- Reduced inflammatory signaling
- Potential nerve repair support
- Reduced neuropathic pain signaling
- Improved tissue recovery mechanisms
- Protection against inflammatory tissue damage
6. Potential Benefits
- Potential neuropathy symptom reduction
- Reduced inflammatory signaling
- Possible chronic pain support
- Potential nerve regeneration support
- Improved tissue recovery mechanisms
- Non-erythropoietic tissue protective signaling
7. Potential Risks / Side Effects
Moderate
- Injection site irritation
- Headaches
- Fatigue
- Nausea
- Dizziness
- Limited long-term human safety data
- Potential immune signaling alterations
8. Half-Life
ARA-290 has an extremely short estimated half-life commonly referenced in the range of approximately 2–5 minutes.
Because of this short duration, administration timing and consistency are frequently emphasized in experimental protocols.
9. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Avoid repeated freeze-thaw cycles
- Maintain sterile handling practices during preparation
10. Contraindications / Warnings
- Pregnancy or breastfeeding
- Active autoimmune disorders
- Uncontrolled inflammatory disease
- Known hypersensitivity to peptide compounds
11. Research References
- PubMed
- NIH Publications
- Neuropathy and tissue repair literature
- Peer-reviewed inflammatory signaling journals
CKF Tide Tables 